Commentary|Videos|November 16, 2023
Closing Thoughts on Recent Data in GI Cancers From ESMO 2023
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
The approval of the adjuvant atezolizumab combination in dMMR colon cancer is supported by the phase 3 ATOMIC trial.
FDA grants 2 breakthrough therapy designations to Temab-A, speeding development for hard-to-treat colorectal cancer and c-Met–expressing lung cancer.
Adding zabilugene almadenorepvec to standard gemcitabine/nab-paclitaxel extends survival and response in newly diagnosed metastatic pancreatic cancer, with manageable safety signals.
Advertisement
Advertisement